Roche Acquires PathAI for $1.05 Billion to Bolster AI Diagnostics Tools
- May 11
- 1 min read
PathAI has entered into a definitive merger agreement to be acquired by Roche to transform AI-driven diagnostics. The pharma giant has agreed to pay $750 million upfront, with up to $300 million in additional payments subject to targets. PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory efficiency. According to the companies' joint statement, these integrated capabilities will accelerate the shift from broad intervention toward personalized healthcare for patients. Learn more about the announcement through this link https://www.roche.com/media/releases/med-cor-2026-05-07.
